Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial

Jason Gotlib, MD, Hanneke C. Kluin-Nelemans, MD, PhD, Tracy I. George, MD, Cem Akin, MD, PhD, Karl Sotlar, MD, Olivier Hermine, Farrukh Awan, MD, MS, Elizabeth Hexner, MD, Michael Mauro, MD, Rodica Morariu, MD, Margaret Squier, MD, PhD, Matthieu Villeneuve, Fabienne Emery-Salbert, MSc, John Coombs, PharmD, MBA, Karin Hartmann, MD, Hans-Peter Horny, MD, Peter Valent, MD, Andreas Reiter, MD

Blood (2013) 122 (21): 106.

https://doi.org/10.1182/blood.V122.21.106.106

Published: 2013

Journal Articles

Impact Of Ruxolitinib On The Natural History Of Patients With Primary Myelofibrosis: A Retrospective Comparison Of The DIPSS and The Comfort-2 Cohorts

Francesco Passamonti, MD, Margherita Maffioli, MD, Francisco Cervantes, MD, PhD, Alessandro M. Vannucchi, MD, PhD, Enrica Morra, MD, Tiziano Barbui, MD, Caramazza Domenica, MD, Elisa Rumi, MD, Gisslinger Heinz, Laurent Knoops, MD, PhD, Barbara Mora, MD, Norbert Hollaender, PhD, Margaret Squier, MD, PhD, Cristiana Pascutto, Claire N Harrison, DM, FRCP, FRCPath, Mario Cazzola, MD

Blood (2013) 122 (21): 4066.

https://doi.org/10.1182/blood.V122.21.4066.4066

Published: 2013

Journal Articles

The Combination Of JAK Inhibitor, Ruxolitinib, and PIM Inhibitor, LGH447, In Preclinical Models Of Myeloproliferative Neoplasia

Abdel Saci, Ph.D., Maria Pinzon-Ortiz, Dannie Wang, Xianhui Rong, Joseph Growney, Ph.D., Margaret Squier, MD, PhD, Thomas Radimerski, PhD, K. Gary Vanasse, Giordano Caponigro, Pablo D Garcia, PhD, Z. Alexander Cao

Blood (2013) 122 (21): 4100.

https://doi.org/10.1182/blood.V122.21.4100.4100

Published: 2013

Journal Articles

KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial

Jason Gotlib, MD, MS, Hanneke C. Kluin-Nelemans, MD, PhD, Tracy I. George, MD, Cem Akin, MD, PhD, Karl Sotlar, MD, Olivier Hermine, MD, PhD, Farrukh Awan, MD, MS, Elizabeth Hexner, MD, Michael J. Mauro, MD, Rodica Morariu, MD, Margaret Squier, MD, PhD, Matthieu Villeneuve, Fabienne Emery-Salbert, MSc, Karin Hartmann, MD, Hans-Peter Horny, MD, Peter Valent, MD, Andreas Reiter, MD

Blood (2012) 120 (21): 799.

https://doi.org/10.1182/blood.V120.21.799.799

Published: 2012

Journal Articles

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with Cytarabine and Mitoxantrone As Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Richard F. Schlenk, MD, Jürgen Krauter, MD, Markus Schaich, MD, Didier Bouscary, MD, PhD, Hervé Dombret, Ivo J. Winiger, MD, Margaret Squier, MD, PhD, Anita Zahlten, PhD, Lu Wang, PhD, Oliver G. Ottmann, MD, PhD

Blood (2011) 118 (21): 423.

https://doi.org/10.1182/blood.V118.21.423.423

Published: 2011

Journal Articles

Determination of a Phase II Dose of Panobinostat in Combination with 5-Azacitidine in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Oliver G. Ottmann, MD, PhD, Daniel J. DeAngelo, MD, PhD, Guillermo Garcia-Manero, Michael Lübbert, Anand Jillella, MD, Mikkael A. Sekeres, MD, MS, Anita Zahlten, PhD, Margaret Squier, MD, PhD, Suddhasatta Acharyya, PhD, Ivo J. Winiger, MD, Pierre Fenaux, MD, PhD

Blood (2011) 118 (21): 459.

https://doi.org/10.1182/blood.V118.21.459.459

Published: 2011

Journal Articles

A Phase Ib Dose-Finding Study of Oral Panobinostat In Combination with Cytarabine (ara-C) and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia (AML)

Jürgen Krauter, MD, Richard F. Schlenk, MD, Markus Schaich, MD, Didier Bouscary, MD, Hervé Dombret, MD, Ivo J. Winiger, MD, Margaret Squier, MD, PhD, Bourras-Rezki Bengoudifa, Oliver G. Ottmann, MD

Blood (2010) 116 (21): 3310.

https://doi.org/10.1182/blood.V116.21.3310.3310

Published: 2010

Journal Articles

Phase Ib Study of Oral Panobinostat In Combination with 5-Azacitidine (5-aza) In Patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Pierre Fenaux, MD, PhD, Daniel J DeAngelo, MD, PhD, Guillermo Garcia-Manero, MD, Michael Lübbert, MD, PhD, Anand P. Jillella, MD, Mikkael A. Sekeres, MD, MS, Ivo J. Winiger, MD, Margaret Squier, MD, PhD, Xiaodong Li, PhD, Oliver G. Ottmann, M.D.

Blood (2010) 116 (21): 4957.

https://doi.org/10.1182/blood.V116.21.4957.4957

Published: 2010

NARROW

Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial

Impact Of Ruxolitinib On The Natural History Of Patients With Primary Myelofibrosis: A Retrospective Comparison Of The DIPSS and The Comfort-2 Cohorts

The Combination Of JAK Inhibitor, Ruxolitinib, and PIM Inhibitor, LGH447, In Preclinical Models Of Myeloproliferative Neoplasia

KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with Cytarabine and Mitoxantrone As Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Determination of a Phase II Dose of Panobinostat in Combination with 5-Azacitidine in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

A Phase Ib Dose-Finding Study of Oral Panobinostat In Combination with Cytarabine (ara-C) and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia (AML)

Phase Ib Study of Oral Panobinostat In Combination with 5-Azacitidine (5-aza) In Patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only